Novartis News | finanzen.ch

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Aktion

Portfolio

Watchlist

25.10.17	Novartis confirms leadership in multiple sclerosis (MS) with scientific advancements and new data presented at ECTRIMS (GlobeNewswire)
24.10.17	Novartis steigert im dritten Quartal Umsatz und Gewinn in allen Divisionen (GlobeNewswire)
24.10.17	Novartis delivered growth on top and bottom line in all divisions in Q3 (GlobeNewswire)
23.10.17	Novartis combination adjuvant therapy Tafinlar® + Mekinist® receives FDA Breakthrough Therapy Designation for stage III BRAF V600 mutation-positive melanoma patients (GlobeNewswire)
18.10.17	Novartis drug Revolade® shows long-term disease control for chronic/persistent immune thrombocytopenia (ITP) (GlobeNewswire)
06.10.17	Alcon receives CE Mark for first-of-its-kind AutonoMe(TM) preloaded intraocular lens (IOL) delivery system with Clareon® IOL (GlobeNewswire)
02.10.17	Alcon introduces new innovations in cataract surgery at European Society of Cataract & Refractive Surgeons 2017 annual congress (GlobeNewswire)
28.09.17	Novartis and UC Berkeley collaborate to tackle 'undruggable' disease targets (GlobeNewswire)
22.09.17	Novartis and The Max Foundation transform pioneering cancer access program for people in lower-income countries (GlobeNewswire)
20.09.17	Novartis drug Rydapt® (midostaurin) receives EU approval for newly diagnosed FLT3-mutated acute myeloid leukemia (AML) and three types of advanced systemic mastocytosis (SM) (GlobeNewswire)
16.09.17	Novartis' Xolair® confirms re-treatment efficacy in chronic spontaneous urticaria patients after treatment interruption (GlobeNewswire)
14.09.17	Sandoz proposed biosimilar adalimumab matches reference biologic in terms of efficacy and safety in long-term study (GlobeNewswire)
13.09.17	Novartis' Cosentyx® sets new benchmark in psoriasis with robust 5-year sustained Phase III efficacy and safety data (GlobeNewswire)
12.09.17	Sandoz proposed biosimilar rituximab accepted for review by the FDA (GlobeNewswire)
11.09.17	Novartis Phase III study demonstrates adjuvant Tafinlar® + Mekinist® reduced the risk of disease recurrence by 53% in patients with resected BRAF V600 mutation-positive melanoma (GlobeNewswire)
09.09.17	Novartis presents new data at EURETINA 2017 confirming Lucentis® efficacy and durability vs aflibercept (GlobeNewswire)
07.09.17	Novartis presents new analysis demonstrating AMG 334 (erenumab) significantly reduced monthly migraine days in patients who failed previous preventive therapies (GlobeNewswire)
05.09.17	Novartis landmark Phase III trial shows fingolimod significantly reduces relapses in children and adolescents with MS (GlobeNewswire)
04.09.17	Novartis announces CEO Joseph Jimenez to retire from Novartis in 2018. Vasant Narasimhan appointed CEO, effective February 1, 2018. (GlobeNewswire)
04.09.17	Novartis gibt Rücktritt von CEO Joseph Jimenez per 2018 bekannt. Ernennung von Vasant Narasimhan zum neuen CEO auf 1. Februar 2018. (GlobeNewswire)
30.08.17	Novartis receives first ever FDA approval for a CAR-T cell therapy, Kymriah(TM) (CTL019), for children and young adults with B-cell ALL that is refractory or has relapsed at least twice (GlobeNewswire)
27.08.17	Novartis announces analysis published in The Lancet showing ACZ885 reduced lung cancer mortality by 77% in the CANTOS study with further studies planned (GlobeNewswire)
27.08.17	Novartis Phase III CANTOS study demonstrates that targeting inflammation with ACZ885 reduces cardiovascular risk (GlobeNewswire)
24.08.17	Novartis appoints Bertrand Bodson as Chief Digital Officer (GlobeNewswire)
24.08.17	Novartis Kisqali® (ribociclib) receives EU approval as first-line treatment for HR+/HER2- locally advanced or metastatic breast cancer in combination with any aromatase inhibitor (GlobeNewswire)
21.08.17	Novartis and Medicines for Malaria Venture launch patient trial in Africa for KAF156, a novel compound against multidrug-resistant malaria (GlobeNewswire)
21.08.17	Novartis und Medicines for Malaria Venture starten in Afrika eine Patientenstudie mit KAF156, einem neuartigen Wirkstoff gegen multiresistente Malaria (GlobeNewswire)
25.07.17	Sandoz expands partnership with World Child Cancer, to help children access treatment in four developing countries (GlobeNewswire)
21.07.17	Novartis receives positive CHMP opinion for Rydapt® (midostaurin) for newly diagnosed FLT3-mutated acute myeloid leukemia (AML) and three types of advanced systemic mastocytosis (SM) (GlobeNewswire)
18.07.17	Q2 results confirm full year guidance. Strong pipeline results underpin potential of several highly innovative products (GlobeNewswire)
18.07.17	Die Ergebnisse im zweiten Quartal bestätigen die Jahresprognosen - starke Forschungs- und Entwicklungsresultate untermauern das Potenzial einiger hoch innovativer Produkte (GlobeNewswire)
14.07.17	Novartis confirms 5 year data for first and only fully-human IL-17A inhibitor Cosentyx® reinforcing sustained efficacy and safety profile in psoriasis (GlobeNewswire)
12.07.17	Novartis CAR-T cell therapy CTL019 unanimously (10-0) recommended for approval by FDA advisory committee to treat pediatric, young adult r/r B-cell ALL (GlobeNewswire)
23.06.17	NEJM publishes full analysis of Rydapt® (midostaurin) Phase III RATIFY trial in newly diagnosed FLT3-mutated acute myeloid leukemia (AML) (GlobeNewswire)
25.04.17	Novartis erzielt Umsatzsteigerungen in allen Divisionen (kWk1), wobei Wachstumstreiber wie Cosentyx und Entresto die Einbussen durch Generika mehr als wettmachen; Innovationsdynamik setzt sich fort (GlobeNewswire)
28.02.17	Novartis Aktionäre genehmigen an der ordentlichen Generalversammlung alle Anträge des Verwaltungsrats (GlobeNewswire)
31.01.17	Novartis drug Votubia® receives EU approval to treat refractory partial-onset seizures in patients with TSC (GlobeNewswire)
25.01.17	Novartis erzielt 2016 solide Ergebnisse, wobei die Wachstumsprodukte[1] den Verlust der Exklusivrechte für Gleevec in den USA wettmachen; Innovationsdynamik hält an; Aktienrückkauf angekündigt (GlobeNewswire)
20.12.16	Novartis bolsters ophthalmology pipeline through acquisition of Encore Vision, Inc. (GlobeNewswire)
16.12.16	Novartis bolsters innovative dermatology portfolio through acquisition of Ziarco Group Limited (GlobeNewswire)
12.12.16	Novartis launches SMS for Life 2.0 in Nigeria to help improve access to essential medicines (GlobeNewswire)
12.12.16	Novartis führt "SMS for Life 2.0" in Nigeria ein, um den Zugang zu unentbehrlichen Arzneimitteln zu verbessern (GlobeNewswire)
05.12.16	Novartis survey uncovers real-world burden of myeloproliferative neoplasms (rare blood cancers) on daily activity and ability to work (GlobeNewswire)
05.12.16	New interim data demonstrate Sandoz proposed biosimilar rituximab has equivalent efficacy to reference product (GlobeNewswire)
29.11.16	Novartis Access shares one-year learnings and announces memorandum of understanding with Rwanda (GlobeNewswire)
29.11.16	Novartis Access informiert über Erfahrungen im ersten Jahr und gibt Memorandum of Understanding mit Ruanda bekannt (GlobeNewswire)
21.11.16	Novartis acquires Selexys Pharmaceuticals Corporation and SelG1 antibody for reduction of pain crises in sickle cell disease (SCD) (GlobeNewswire)
21.11.16	Novartis commends publication of major report which recommends broad use of dual bronchodilators to treat COPD (GlobeNewswire)
18.11.16	Innovative study with three treatment switches confirms Sandoz biosimilar etanercept has equivalent efficacy to originator (GlobeNewswire)
16.11.16	Novartis announces AMG 334 significantly reduces monthly migraine days in second pivotal Phase III episodic migraine study (GlobeNewswire)

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Sonova Hldg	295.60	0.96 %	K V
Lonza Grp	531.00	0.53 %	K V
Alcon	76.02	0.34 %	K V
Roche Hldg G	247.40	0.28 %	K V
ABB	48.86	0.27 %	K V
Swisscom	498.40	-0.62 %	K V
UBS Group	26.71	-0.67 %	K V
Zurich Insur Gr	533.00	-0.97 %	K V
Holcim	86.10	-1.01 %	K V
Sika	213.20	-2.47 %	K V

mehr

20.12.24		Freundlicher Handel in New York: Dow Jones beendet die Sitzung weit in der Gewinnzone
20.12.24		Handel in New York: Am Freitagnachmittag Gewinne im Dow Jones
20.12.24		Dow Jones aktuell: Dow Jones notiert am Mittag im Plus
20.12.24		Börse New York in Grün: So steht der NASDAQ 100 aktuell
20.12.24		Handel in Europa: STOXX 50 schliesst im Minus
20.12.24		Schwacher Handel: SMI schliesst mit Verlusten
20.12.24		SPI-Handel aktuell: SPI zum Handelsende leichter
20.12.24		Verluste in Europa: Euro STOXX 50 letztendlich leichter